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Abstract
The Pediatric Cardiac Genomics Consortium (PCGC) designed the Congenital Heart Dis-
ease Genetic Network Study to provide phenotype and genotype data for a large congenital
heart defects (CHDs) cohort. This article describes the PCGC cohort, overall and by major
types of CHDs (e.g., conotruncal defects) and subtypes of conotrucal heart defects (e.g.,
tetralogy of Fallot) and left ventricular outflow tract obstructions (e.g., hypoplastic left heart
syndrome). Cases with CHDs were recruited through ten sites, 2010–2014. Information on
cases (N = 9,727) and their parents was collected through interviews and medical record
abstraction. Four case characteristics, eleven parental characteristics, and thirteen parent-
reported neurodevelopment outcomes were summarized using counts and frequencies and
compared across CHD types and subtypes. Eleven percent of cases had a genetic diagno-
sis. Among cases without a genetic diagnosis, the majority had conotruncal heart defects
(40%) or left ventricular outflow tract obstruction (21%). Across CHD types, there were
significant differences (p<0.05) in the distribution of all four case characteristics (e.g.,
sex), four parental characteristics (e.g., maternal pregestational diabetes), and five
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neurodevelopmental outcomes (e.g., learning disabilities). Several characteristics (e.g.,
sex) were also significantly different across CHD subtypes. The PCGC cohort is one of the
largest CHD cohorts available for the study of genetic determinants of risk and outcomes.
The majority of cases do not have a genetic diagnosis. This description of the PCGC cohort,
including differences across CHD types and subtypes, provides a reference work for investi-
gators who are interested in collaborating with or using publically available resources from
the PCGC.
Introduction
Congenital heart defects (CHDs) occur in approximately 1% of births and are among the most
common and serious birth defects [1, 2]. While advances in treatment have reduced CHD-
related mortality, CHDs remain the leading cause of birth defect-related infant deaths [3].
Moreover, the growing numbers of CHD survivors are at risk for a range of disease-related
morbidities [4, 5] and have reduced life-expectancies compared to their unaffected
contemporaries [4].
CHDs include a broad spectrum of malformations that differ with respect to morphology,
physiology, and clinical outcome. Although CHD risk is thought to be influenced by both
environmental and genetic factors, relatively few specific CHD risk factors have been identified
and the extent to which the etiology of different CHDs differ or overlap is unknown. Large epi-
demiological studies, such as the National Birth Defect Prevention Study, have identified a few
non-genetic risk factors for CHDs including maternal pre-gestational diabetes, obesity, and
smoking [6–10]. To accelerate understanding of the genetic contribution to CHDs, the
National Heart, Lung, and Blood Institute formed the Pediatric Cardiac Genomics Consor-
tium (PCGC). The PCGC designed and implemented the Congenital Heart Disease GEnetic
NEtwork Study (CHD GENES) to establish the resources required to undertake comprehen-
sive studies of the genetics of CHDs.
The rationale for, design of, and early results from CHD GENES have been described [11–
14]. In addition, genotype array, exome sequence, whole genome sequence, and RNA sequence
data from CHD GENES participants have been and will continue to be posted to dbGAP
(dbGAP Accession: phs000571.v3.p2, January 2016). In this article, we provide a description of
the phenotypes, characteristics, and selected parent-reported neurodevelopmental outcomes
of the PCGC cohort, as a resource for the broader CHD research community.
Methods
Study population
Subject recruitment and data collection for CHD GENES have been described [11]. Briefly,
subjects were recruited from five main sites (Children’s Hospital of Philadelphia, Columbia
University Medical Center, Harvard Medical School including Boston Children’s Hospital and
Brigham and Women’s Hospital, Icahn School of Medicine at Mount Sinai, and Yale School of
Medicine) and four satellite sites (Children’s Hospital of Los Angeles, Cohen Children’s Medi-
cal Center, University College London, and University of Rochester Medical Center) from
December 2010 through November 2014. Recruitment methods were center-specific, but gen-
erally included ascertainment of cases at the time of hospital admission or an outpatient visit.
The study protocol was approved by an Institutional Review Board for each site. All study
Cohort description of CHD GENES
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participants (or their parent/guardian) provided written informed consent. The Institutional
Review Board at the University of Texas Health Science Center at Houston approved the study
protocol for the data analyzed and presented in this article.
Patients with any diagnosis of CHD (except as noted below), regardless of sex, age, and
race/ethnicity were eligible to participate. Patients with a genetic diagnosis were eligible to par-
ticipate, but preference for enrolling such patients may have varied across study sites. Patients
with isolated patent foramen ovale, prematurity-related isolated patent ductus arteriosus, pul-
monary stenosis related to a twin-twin transfusion, and cardiomyopathy without a CHD were
not eligible. Cardiac diagnoses were confirmed by review of imaging (e.g., echocardiogram)
and operative reports. Information on genetic testing, genetic physical exams, and extracardiac
malformations was abstracted from medical records. In addition, information on cases and
their parents was obtained during subject and family interviews. Cases that did not participate
in the interviews were excluded from this report.
Data collected by interview included race/ethnicity, sex, birth weight, and maternal and
paternal ages at the time of the cases’ birth. Data were also collected on maternal characteris-
tics, including pre-pregnancy height and weight (to calculate pre-pregnancy body mass index),
pre-gestational diabetes, gestational diabetes, epilepsy or seizure during pregnancy, and educa-
tion level. For cases who were1 year of age at recruitment, interview data were also collected
on maternal smoking and alcohol use during the first trimester, any folic acid supplementation
six months before pregnancy, and parity. For cases who were>1 year at recruitment, the inter-
view included questions related to neurodevelopmental outcomes (e.g., attention deficit hyper-
activity disorder, autism spectrum).
CHD diagnoses assigned using the International Paediatric and Congenital Cardiac Codes
(http://www.ipccc.net/) were manually reviewed by two of the authors (S.E and E.G.) and
cases were assigned to one of seven types of CHDs: laterality disorder (LAT), conotruncal
heart defect (CTD), atrioventricular septal defect (AVCD), left ventricular outflow tract
obstruction (LVOT), right ventricular outflow tract obstruction (RVOT), atrial septal defect
(ASD), and other. These groups are based on subsets of lesion that are thought to share genetic
and mechanistic underpinnings and are defined in Table 1. Cases were categorized using a
hierarchical approach. First, cases with a laterality disorder, regardless of other findings, were
Table 1. Diagnostic types of congenital heart defect in the Pediatric Cardiac Genetic Consortium Cohort.
Diagnostic Type Abbreviation Description
Laterality Disorder LAT Includes cases with at least one of the following laterality disorders: dextrocardia, interrupted inferior vena cava,
atrial situs abnormalities (i.e. ambiguous/inversus), L-transposition of the great arteries (ventricular inversion),
asplenia/polysplenia, bronchial isomerism, abdominal laterality disorder, intestinal malrotation.
Conotruncal heart defect CTD Tetralogy of Fallot, truncus arteriosus, interrupted aortic arch, double outlet right ventricle, d-transposition of the
great arteries, isolated conoventricular or posterior malalignment or conoseptal hypoplasia type ventricular septal
defect, and isolated aortic arch anomalies
Atrioventricular canal defect AVCD Primum atrial septal defect, transitional atrioventricular canal defect, complete atrioventricular canal defect,
isolated cleft mitral valve
Left ventricular outflow tract
obstruction
LVOT Bicuspid aortic valve/aortic valve stenosis, coarctation of the aorta, hypoplastic left heart syndromea, mitral valve
anomalies
Right ventricular outflow tract
obstruction
RVOT Triscupid valve atresia/stenosis with or without pulmonary valve atresia/stenosis with normally related great
arteries, pulmonary valve atresia/stenosis with normally related great arteries
Atrial Septal Defect ASD Secundum or sinus venosus type
Other Complex malformations (e.g., double inlet left ventricle), isolated venous or coronary artery anomalies, isolated
muscular ventricular septal defect, other conditions
a Does not include variants of hypoplastic left heart syndrome such as malaligned atrioventricular canal defect or double outlet right ventricle with mitral atresia.
https://doi.org/10.1371/journal.pone.0191319.t001
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placed in LAT. Next, cases with abnormal conotruncal anatomy (including specific subtypes of
isolated ventricular septal defects), regardless of associated left or right sided obstruction or
atrioventricular canal anomalies, were placed in CTD. Then, cases with atrioventricular canal
abnormalities with normally related great arteries were categorized as AVSD and cases with
left or right sided obstructive lesions with normally related great arteries and normal atrioven-
tricular canals were assigned to LVOT or RVOT, respectively. Finally, cases with an isolated
secundum or sinus venosus type atrial septal defect were assigned to ASD. Cases with any
other CHD diagnosis were assigned to the other group.
Based on data from the interviews and medical records, cases were classified as either hav-
ing 1) an identified genetic diagnosis (i.e. a syndrome or genetic alteration thought to explain
the associated CHD), or 2) no genetic diagnosis. For simplicity, we refer to such cases as “syn-
dromic” and “nonsyndromic”, respectively. Cases classified as nonsyndromic by this scheme
may have had additional non-cardiac anomalies or reported neurodevelopmental deficits.
Statistical analysis
For syndromic cases, we reported counts and frequencies for each specific diagnosis. Given
the clinical heterogeneity within this group, we excluded syndromic cases from subsequent
analyses. For nonsyndromic cases, parental characteristics, case characteristics, and parent-
reported neurodevelopmental outcomes were described using counts and frequencies for dis-
crete variables, and means and standard deviations or median and range for continuous vari-
ables. Due to differences in the education systems in the United States and United Kingdom,
we excluded women who were educated in the United Kingdom in our description of maternal
education. Further, we restricted our analyses of neurodevelopmental outcomes to cases who
were5 years of age at recruitment, since neurodevelopmental deficits may be under-diag-
nosed in younger children. In addition to assessing each of 13 parental-reported (yes/no) neu-
rodevelopmental outcomes, we created a composite neurodevelopmental outcome variable,
indicating a positive parental report for at least one of four conditions: developmental delay,
learning disability, mental retardation, or autism spectrum disorder [13].
We used the chi-square test (or Fisher’s exact test when >20% of cells had an expected cell
count<5) to compare the distribution of categorical variables across types of CHDs. For con-
tinuous variables, we used ANOVA or the Kruskal-Wallis test to compare the mean or median,
respectively, across types of CHDs. For ANOVA analyses, we used Levene’s test to check the
assumption of homogeneity of variance. If Levene’s test was significant (p<0.05), we used
Welch’s ANOVA. Analyses of all variables, except neurodevelopmental outcomes, were
repeated in the subset of cases who were1 year of age at recruitment for the following rea-
sons: 1) inaccurate recall of characteristics or events before or during pregnancy is of greater
concern for cases ascertained at older ages than at younger ages; and 2) the distribution of
characteristics across types of CHDs may be influenced by survival. Because of the heterogene-
ity within type of CHDs, analyses were also repeated to compare specific subtypes in the two
largest types of CHDs—CTD and LVOT cases. These analyses were restricted to include sub-
types that included at least 200 cases. For LVOT, cases with aortic stenosis were combined
with cases with bicuspid aortic valve to create a subtype called ‘aortic valve disease.’
Because differences in the distribution of neurodevelopmental outcomes across types of
CHDs may be influenced by factors other than the CHD diagnosis, we used logistic regression
to control for potential confounders determined a priori from the literature [15]: maternal
education, case race/ethnicity, sex, birth weight (low [<2,500g], normal [2,500–4,000g], high
[>4,000g]), and extracardiac malformations (yes/no). Further, as neurodevelopmental deficits
may be under-diagnosed in younger cases, we also adjusted for case age at the time of
Cohort description of CHD GENES
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recruitment. Adjusted analyses were not conducted for the CTD and LVOT subtypes because
of the relatively small numbers of cases with specific outcomes (e.g., double outlet right ventri-
cle with autism spectrum, N = 4).
All analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC). P-values
<0.05 were considered statistically significant.
Results
Data were available for 9,727 cases, including 1,034 (11%) with a genetic diagnosis. The most
common syndromic diagnoses were trisomy 21 (38%) and DiGeorge syndrome (DGS)/Velo-
cardiofacial syndrome (VCFS)/22q11.2 deletion (24%) (Table 2). Among cases with trisomy
21, the most common CHDs were AVCDs (52%) and CTDs (35%). Among cases with DGS/
VCFS/22q11.2 deletion, the most common CHD was CTDs (96%) (S1 Table).
The nonsyndromic cases are described in Table 3 and the distributions of CHD subtypes
(e.g., tetralogy of Fallot, truncus arteriosus) are provided in the S2 Table. The largest subsets of
CHDs were CTD (40%) and LVOT (21%). The majority of cases were non-Hispanic White
(59%) and male (55%). In addition, cases were predominantly born in the United States (86%),
had normal birth weight (77%), did not have extracardiac malformations (76%), and were >1
year of age at recruitment (69%).
The description of the nonsyndromic cases, by type of CHDs, is provided in Table 4. The
distributions of three maternal characteristics, across the six types of CHDs, were significantly
different: body mass index (p = 0.002), pre-gestational diabetes (p<0.001), and education
Table 2. Syndromic diagnoses in the Pediatric Cardiac Genetic Consortium Cohort.
Syndrome N
(n = 1,034)
%
Alagille 19 1.8
CHARGE 24 2.3
DGS/VCFS/22q11.2 Deletion 251 24.3
Ehlers Danlos syndrome 9 0.9
GATA4a 13 1.3
Goldenhar 12 1.2
Holt Oram 9 0.9
Kabuki 9 0.9
Noonan 47 4.5
Trisomy 21 392 37.9
Turner Syndrome 33 3.2
VATER 9 0.9
VACTERL +/- VATER 56 5.4
Williams 41 4.0
Other Syndromes 68 6.6
Other Autosomal Trisomies 11 1.1
Other X Chromosome Aneuploidy 7 0.7
Other Chromosome Abnormalitiesb 16 1.6
Multiple Syndromesc 8 0.8
DGS—DiGeorge Syndrome; VCFS—Velocardiofacial syndrome.
a 11 8p23.1 deletion, 1 deletion/duplication, 1 inversion.
b Ring chromosome, translocation, isochromosome.
c Cases had >1 syndrome.
https://doi.org/10.1371/journal.pone.0191319.t002
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(p<0.001). For example, the proportion of cases with an obese mother ranged from 10%
(ASD) to 19% (AVCD); the proportion with maternal pre-gestational diabetes ranged from
1% (ASD) to 5% (LAT); and the proportion of cases with a mother with less than a high school
education ranged from 4% (AVCD) to 14% (ASD). A significant difference across types of
CHDs was also observed for paternal age (p = 0.02) (Table 4). When analyses were restricted
to cases1 year at recruitment, similar results were obtained for maternal education and
paternal age. However, in this subset, differences were not statistically significant across type
of CHD for maternal body mass index or pre-gestational diabetes (S3 Table).
Table 3. Description of nonsyndromica cases in the Pediatric Cardiac Genetic Consortium Cohort.
Nb
(n = 8,693)
%
CHD Categories
LAT 779 9.0
CTD 3,500 40.3
AVCD 314 3.6
LVOT 1,834 21.1
RVOT 688 7.9
ASD 770 8.9
Other 808 9.3
Race/Ethnicity
White 5,110 59.0
Hispanic 1,929 22.3
Black 601 6.9
Asian 574 6.6
Otherc 447 5.2
Sex
Male 4,778 55.0
Female 3,914 45.0
Country of Birth
United States 7,419 85.5
United Kingdom 599 6.9
Other 661 7.6
Birth weight (g)
Low (<2,500) 1,244 15.8
Normal (2,500–4,000) 6,074 77.1
High (>4,000) 560 7.1
Extracardiac malformations
Yes 2,113 24.4
No 6,563 75.7
Age at Recruitment
1 year 2,659 30.7
>1 year 6,002 69.3
ASD—atrial septal defect, AVCD—atrioventricular canal defect, CHD—congenital heart defect, CTD—conotruncal
heart defect, LAT—laterality disorder, LVOT—left ventricular outflow tract, RVOT—right ventricular outflow tract.
a No recognized clinical syndrome but may have noncardiac anomalies.
b May not sum to total because of missing data.
c Includes Native American/Alaskan, Pacific Islander, and >1 race.
https://doi.org/10.1371/journal.pone.0191319.t003
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Table 4. Demographic, pregnancy, and birth history comparisons of nonsyndromica cases across major types of congenital heart defect in the Pediatric Cardiac
Genetic Consortium Cohort.
All cases
Cases1 year
LAT
n = 779
n = 220
CTD
n = 3,500
n = 1,322
AVCD
n = 314
n = 93
LVOT
n = 1,834
n = 536
RVOT
n = 688
n = 188
ASD
n = 770
n = 57
p-valueb Totalc
n = 8,693
n = 2,656
Mean ± SD Mean ± SD
Maternal Age 29.3 ± 6.0 29.9 ± 5.8 29.6 ± 5.7 29.9 ± 5.9 29.6 ± 5.8 29.9 ± 6.1 0.15 29.8 ± 5.9
Paternal Age 31.7 ± 6.6 32.7 ± 6.7 32.3 ± 6.7 32.2 ± 6.6 32.3 ± 6.8 32.6 ± 6.7 0.02 32.4 ± 6.6
Mother Nf (%) Nf (%)
Body Mass Index (kg/m2) 0.002
Underweight (<18.5) 56 (8.7) 191 (6.4) 18 (6.6) 85 (5.4) 29 (5.0) 36 (5.7) 459 (6.2)
Normal (18.5-<25) 363 (56.5) 1,814 (60.7) 152 (55.7) 952 (60.0) 338 (57.9) 418 (66.1) 4,458 (60.4)
Overweight (25-<30) 142 (22.1) 587 (19.7) 50 (18.3) 327 (20.6) 135 (23.1) 117 (18.5) 1,494 (20.2)
Obese (30) 82 (12.8) 395 (13.2) 53 (19.4) 222 (14.0) 82 (14.0) 61 (9.7) 973 (13.2)
Epilepsy/Seizure 0.09
Yes 1 (0.1) 19 (0.6) 1 (0.3) 6 (0.3) 8 (1.2) 3 (0.4) 45 (0.5)
No 737 (99.9) 3,323 (99.4) 302 (99.7) 1751 (99.7) 638 (98.8) 718 (99.6) 8,233 (99.5)
Pregestational Diabetes <0.001
Yes 34 (4.6) 102 (3.1) 7 (2.3) 27 (1.5) 11 (1.7) 10 (1.4) 213 (2.6)
No 704 (95.4) 3,242 (97.0) 295 (97.7) 1,731 (98.5) 635 (98.3) 710 (98.6) 8,062 (97.4)
Gestational Diabetes 0.58
Yes 59 (8.1) 243 (7.3) 22 (7.3) 112 (6.4) 47 (7.3) 45 (6.3) 591 (7.2)
No 673 (91.9) 3,083 (92.7) 279 (92.7) 1,640 (93.6) 599 (92.7) 673 (93.7) 7,651 (92.8)
Educationd <0.001
<High school 73 (10.6) 258 (8.6) 12 (4.4) 142 (8.5) 59 (9.5) 91 (13.5) 715 (9.4)
High school 176 (25.6) 659 (21.8) 57 (20.8) 333 (20.0) 140 (22.6) 150 (22.3) 1,673 (21.9)
Partial college 140 (20.4) 723 (24.0) 87 (31.8) 410 (24.6) 146 (23.6) 153 (22.7) 1,832 (23.9)
College or higher 299 (43.5) 1,377 (45.5) 118 (43.1) 779 (46.8) 274 (44.3) 280 (41.5) 3,431 (44.8)
Paritye 0.16
Primiparous 84 (38.7) 623 (47.4) 42 (45.7) 229 (43.1) 78 (43.1) 26 (45.6) 1,182 (44.8)
Multiparous 133 (61.3) 692 (52.6) 50 (54.4) 303 (57.0) 103 (56.9) 31 (54.4) 1,457 (55.2)
Folic Acide 0.36
Yes 116 (54.0) 769 (58.8) 50 (53.8) 283 (53.6) 101 (56.4) 31 (54.4) 1,468 (55.9)
No 99 (46.1) 539 (41.2) 43 (46.2) 245 (46.4) 78 (43.6) 26 (45.6) 1,157 (44.1)
Smokinge 0.45
Yes 24 (11.1) 119 (9.1) 7 (7.5) 44 (8.3) 11 (6.0) 3 (5.3) 220 (8.3)
No 193 (88.9) 1,196 (91.0) 86 (92.5) 487 (91.7) 171 (94.0) 54 (94.7) 2,419 (91.7)
Alcohole 0.60
Yes 18 (8.2) 151 (11.5) 8 (8.6) 54 (10.2) 16 (8.8) 5 (8.8) 277 (10.5)
No 201 (91.8) 1,160 (88.5) 85 (91.4) 477 (89.8) 166 (91.2) 52 (91.2) 2,359 (89.5)
Case
Race/Ethnicity <0.001
White 437 (56.5) 2,027 (58.2) 202 (64.3) 1,225 (67.0) 402 (58.4) 404 (52.7) 5,110 (59.0)
Hispanic 179 (23.1) 729 (20.9) 51 (16.2) 391 (21.4) 159 (23.1) 197 (25.7) 1,929 (22.3)
Black 62 (8.0) 251 (7.2) 30 (9.6) 87 (4.8) 55 (8.0) 42 (5.5) 601 (6.9)
Asian 52 (6.7) 268 (7.7) 13 (4.1) 63 (3.4) 35 (5.1) 83 (10.8) 574 (6.6)
Other 44 (5.7) 208 (6.0) 18 (5.7) 63 (3.4) 37 (5.4) 41 (5.4) 447 (5.2)
Sex <0.001
Male 445 (57.1) 1,971 (56.3) 122 (38.9) 1,206 (65.8) 337 (49.0) 287 (37.3) 4,778 (55.0)
Female 334 (42.9) 1,528 (43.7) 192 (61.2) 628 (34.2) 351 (51.0) 483 (62.7) 3,914 (45.0)
(Continued )
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Although, overall, CHD cases were significantly (p<0.001) more likely to be male (55%)
than female, males were predominant in only three of the types of CHDs (LAT, CTD and
LVOT) (Table 4). Significant differences across types of CHDs were also observed for case
race/ethnicity, birth weight, and extracardiac malformations (p<0.001). For example, the pro-
portion of cases that were non-Hispanic white ranged from 53% (ASD) to 67% (LVOT); the
proportion of cases with a low birth weight ranged from 11% (LVOT) to 19% (CTD, ASD);
and the proportion of cases that had extracardiac malformations ranged from 19% (RVOT) to
51% (LAT). Similar results were obtained when analyses were restricted cases 1 year at
recruitment (S3 Table).
Neurodevelopmental outcomes
In nonsyndromic cases, the description of neurodevelopmental outcomes by type of CHDs
and the p-values from the unadjusted analyses are provided in Table 5. Differences across
types of CHDs were observed for attention deficit hyperactivity disorder (p = 0.03), depression
(p = 0.01), developmental delay (p = 0.003), learning disability (p<0.001), repeated grade
(p<0.001), and the composite neurodevelopmental outcome variable (p<0.001). The frequen-
cies of these outcomes were highest for cases with RVOT (attention deficit hyperactivity disor-
der, 10%; depression, 10%) or AVCD (developmental delay, 17%; learning disability, 21%;
repeated grade, 21%; composite measure, 28%) and lowest for cases with ASD (5%, 6%, 8%,
11%, 13%, and 10%, respectively). Results were similar in the adjusted analyses; however, dif-
ferences across types of CHDs were no longer significant for attention deficit hyperactivity dis-
order and depression, and the adjusted model did not converge for autism spectrum and other
neurodevelopmental outcomes.
CTD and LVOT subtypes
Analyses were repeated to assess differences across subtypes within CTDs and LVOTs (S4 and
S5 Tables). Given the relatively small numbers of subtypes of CHDs in these two groups, only
Table 4. (Continued)
All cases
Cases1 year
LAT
n = 779
n = 220
CTD
n = 3,500
n = 1,322
AVCD
n = 314
n = 93
LVOT
n = 1,834
n = 536
RVOT
n = 688
n = 188
ASD
n = 770
n = 57
p-valueb Totalc
n = 8,693
n = 2,656
Birth weight (g) <0.001
Low (<2,500) 89 (12.9) 592 (18.6) 41 (14.3) 188 (11.1) 95 (15.5) 127 (18.6) 1,244 (15.8)
Normal (2,500–4,000) 556 (80.7) 2,380 (74.9) 218 (76.2) 1,358 (80.1) 485 (79.0) 516 (75.4) 6,074 (77.1)
High (>4,000) 44 (6.4) 204 (6.4) 27 (9.4) 149 (8.8) 34 (5.5) 41 (6.0) 560 (7.1)
Extracardiac malformations <0.001
Yes 393 (50.5) 858 (24.5) 69 (22.0) 369 (20.2) 128 (18.6) 151 (19.7) 2,113 (24.4)
No 386 (49.6) 2,638 (75.5) 245 (78.0) 1,462 (79.9) 560 (81.4) 616 (80.3) 6,563 (75.7)
ASD—atrial septal defect, AVCD—atrioventricular canal defect, CTD—conotruncal heart defect, LAT—laterality disorder, LVOT—left ventricular outflow tract, RVOT
—right ventricular outflow tract.
a No recognized clinical syndrome but may have noncardiac anomalies.
b ANOVA test for continuous variables; chi-square test (or Fisher’s exact test when >20% of cells had an expected cell count <5) for categorical variables.
c Includes Other.
d Excluded mothers whose highest education was in the United Kingdom.
e Information only available for cases1 year at recruitment.
f May not sum to total because of missing data.
https://doi.org/10.1371/journal.pone.0191319.t004
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Table 5. Neurodevelopmental outcomes across major types of congenital heart defect for nonsyndromica cases 5 years old in the Pediatric Cardiac Genetic Con-
sortium Cohort.
Cases5 year LAT
n = 412
CTD
n = 1,720
AVCD
n = 145
LVOT
n = 1,045
RVOT
n = 380
ASD
n = 448
p-valueb Totalc
n = 4,587
Ne (%) Ne| (%)
Attention deficit hyperactivity disorder 0.03
Yes 33 (8.0) 163 (9.5) 12 (8.4) 100 (9.7) 37 (9.8) 21 (4.7) 403 (8.9)
No 378 (92.0) 1,545 (90.5) 131 (91.6) 932 (90.3) 341 (90.2) 423 (95.3) 4,148 (91.1)
Anxiety 0.76
Yes 37 (9.0) 169 (9.9) 13 (9.0) 86 (8.3) 38 (10.0) 38 (8.5) 414 (9.1)
No 373 (91.0) 1,538 (90.1) 132 (91.0) 950 (91.7) 341 (90.0) 409 (91.5) 4,146 (90.9)
Autism Spectrum 0.07
Yes 3 (0.7) 41 (2.4) 2 (1.4) 22 (2.1) 5 (1.3) 3 (0.7) 86 (1.9)
No 408 (99.3) 1,673 (97.6) 143 (98.6) 1,017 (97.9) 373 (98.7) 443 (99.3) 4,483 (98.1)
Behavioral 0.09
Yes 15 (3.7) 72 (4.2) 3 (2.1) 26 (2.5) 10 (2.6) 10 (2.2) 150 (3.3)
No 395 (96.3) 1,634 (95.8) 142 (97.9) 1,011 (97.5) 369 (97.4) 437 (97.8) 4,409 (96.7)
Depression 0.01
Yes 29 (7.1) 116 (6.8) 11 (7.6) 45 (4.3) 36 (9.5) 26 (5.8) 286 (6.3)
No 381 (92.9) 1,591 (93.2) 134 (92.4) 996 (95.7) 344 (90.5) 422 (94.2) 4,280 (93.7)
Developmental Delay 0.003
Yes 63 (15.4) 240 (14.0) 25 (17.2) 118 (11.4) 53 (14.1) 37 (8.3) 576 (12.6)
No 346 (84.6) 1,470 (86.0) 120 (82.8) 992 (88.7) 324 (85.9) 411 (91.7) 3,989 (87.4)
Learning Disability <0.001
Yes 85 (20.8) 327 (19.2) 30 (21.4) 166 (16.0) 81 (21.4) 49 (11.0) 796 (17.5)
No 324 (79.2) 1,376 (80.8) 110 (78.6) 874 (84.0) 297 (78.6) 398 (89.0) 3,755 (82.5)
Mental Retardation 0.35
Yes 4 (1.0) 37 (2.2) 2 (1.4) 16 (1.5) 6 (1.6) 4 (0.9) 72 (1.6)
No 406 (99.0) 1,669 (97.8) 143 (98.6) 1,022 (98.5) 371 (98.4) 442 (99.1) 4,483 (98.4)
Obsessive-compulsive disorder 0.38
Yes 5 (1.2) 38 (2.2) 2 (1.4) 15 (1.4) 10 (2.7) 6 (1.3) 78 (1.7)
No 406 (98.8) 1,675 (97.8) 143 (98.6) 1,025 (98.6) 368 (97.4) 442 (98.7) 4,492 (98.3)
Repeated Grade <0.001
Yes 57 (14.7) 246 (15.2) 29 (21.3) 99 (10.1) 58 (16.4) 42 (10.3) 567 (13.2)
No 330 (85.3) 1,376 (84.8) 107 (78.7) 881 (89.9) 296 (83.6) 367 (89.7) 3,727 (86.8)
Seizure Disorder 0.19
Yes 18 (4.4) 53 (3.1) 5 (3.4) 34 (3.3) 14 (3.7) 6 (1.3) 143 (3.1)
No 391 (95.6) 1,657 (96.9) 140 (96.7) 1,005 (96.7) 364 (96.3) 441 (98.7) 4,420 (96.9)
Speech Problem 0.18
Yes 64 (15.6) 271 (15.8) 20 (13.8) 152 (14.6) 49 (12.9) 50 (11.2) 662 (14.5)
No 346 (84.4) 1,442 (84.2) 125 (86.2) 889 (85.4) 330 (87.1) 398 (88.8) 3,909 (85.5)
Other 0.46
Yes 9 (2.2) 40 (2.3) 2 (1.4) 18 (1.7) 7 (1.9) 4 (0.9) 83 (1.8)
No 402 (97.8) 1,673 (97.7) 143 (98.6) 1,021 (98.3) 372 (98.2) 444 (99.1) 4,488 (98.2)
Composited <0.001
Yes 114 (27.7) 425 (24.7) 41 (28.3) 215 (20.6) 106 (27.9) 62 (13.8) 1,044 (22.8)
(Continued)
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unadjusted analyses were conducted. Significant differences across the four subtypes of CTDs
were observed for maternal body mass index (p = 0.03), pre-gestational diabetes (p = 0.04),
and parity (p = 0.01). Significant difference were also observed for infant sex (p<0.001), race/
ethnicity (p<0.001), birth weight (p<0.001), extracardiac malformations (p<0.001), and par-
ent-reported anxiety (p = 0.03).
Across the three subtypes of LVOTs, significant differences were observed for maternal
education (p = 0.005), infant sex (p<0.001), race/ethnicity (p<0.001), birth weight (p = 0.008),
extracardiac malformations (p = 0.04), and several neurodevelopmental outcomes. In general,
adverse neurodevelopmental outcomes appeared to be reported more frequently by parents of
hypoplastic left heart syndrome (HLHS) cases than by parents of aortic valve disease and
coarctation of the aorta cases.
Discussion
Between 2010 and 2014, the PCGC recruited over 9,000 families with a child affected by a
CHD. This cohort is one of only a few large contemporary CHD cohorts that can be used to
study the genetic basis of the causes and consequences of these common and serious birth
defects. The PCGC has established data sharing plans (https://benchtobassinet.com/
ForResearchers/B2BDataSharingPlan.aspx), which include data access through dbGap
(dbGAP Accession: phs000571.v3.p2) and has established a process for proposing ancillary
studies that make use of biospecimens. Hence, the PCGC cohort provides a valuable resource
for the research community. This paper, in conjunction with an earlier report describing the
rationale and design of the PCGC [11], provides investigators with details that should help to
inform their study design (e.g., phenotype selection), analytic plan (e.g., power, subgroup anal-
yses), and interpretation of study results (e.g., study limitations).
As enrollment for the PCGC cohort was through tertiary/quaternary medical centers, it was
skewed toward cases with more severe forms of CHD. However, the cohort includes both
cases with complex and cases with simple lesions, so it is broadly representative of the spec-
trum of clinically significant CHDs. For example, the low frequency of males among cases
with ASDs and AVCDs is consistent with previous findings [10, 16–18]. As recruitment was
center-specific, it is possible that differences in recruitment might have introduced some selec-
tion bias. For instances, the proportion of cases in the PCGC cohort with a genetic diagnosis
(11%) is low compared to population-based estimates (~20%) [19]. This likely reflects the
PCGC recruitment priorities (e.g., nonsyndromic over syndromic) and it is possible that some
centers may have recruited a lower proportion of syndromic cases than other centers.
Table 5. (Continued)
Cases5 year LAT
n = 412
CTD
n = 1,720
AVCD
n = 145
LVOT
n = 1,045
RVOT
n = 380
ASD
n = 448
p-valueb Totalc
n = 4,587
Ne (%) Ne| (%)
No 298 (72.3) 1,295 (75.3) 104 (71.7) 830 (79.4) 274 (72.1) 386 (86.2) 3,543 (77.2)
ASD—atrial septal defect, AVCD—atrioventricular canal defect, CTD—conotruncal heart defect, LAT—laterality disorder, LVOT—left ventricular outflow tract, RVOT
—right ventricular outflow tract.
a No recognized clinical syndrome but may have noncardiac anomalies.
b Unadjusted logistic regression.
c Includes Other.
d Composite variable indicating a positive parental report of autism, developmental delay, learning disability, or mental retardation.
e May not sum to total because of missing data.
https://doi.org/10.1371/journal.pone.0191319.t005
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Because cases of all ages were eligible and information was collected via subject or family
interviews, these data are subject to recall errors. Recall error may account for differences in
estimates obtained from the PCGC and from other studies. For example, this issue might
explain why the proportion of mothers of PCGC cases who reported that they took folic acid
prior to becoming pregnant is relatively high (56%), compared to estimates based on women
who were pregnant or of child-bearing age (<45%) [20–22]. Additionally, because neurodeve-
lopmental outcomes in cases were reported by parents, the reported frequencies may not
reflect the distribution of neurodevelopmental outcomes in the general CHD population [23].
The PCGC did not conduct a case-control study. Since there is no comparable control
group, the cohort cannot be used to study non-genetic risk factors for CHDs and CHD out-
comes. However, differences in the distribution of known CHD risk factors (e.g., race/ethnic-
ity, maternal pre-gestational diabetes) across types and subtypes of CHDs provide potentially
important insights into the data. For example, in the PCGC cohort, the proportion of cases of
Hispanic ethnicity differs across types of CHDs. As similar differences have been observed in
population-based epidemiologic studies [24, 25], this may reflect true underlying differences
in the risk factor profiles of the different CHDs. Nonetheless, these differences might also be
artificial. For example, these differences may be a result of lesion-specific differences in sur-
vival by ethnicity [26] or differences in ascertainment by ethnicity and/or type of CHDs. Either
way, investigators need to be aware of these differences, since they may influence the results
for studies of genetic variants that differ in frequency across ethnic groups.
In summary, we provide a description of the distribution of key variables in the PCGC
cohort and identified differences in the distribution of certain characteristics across types and
subtypes of CHDs. This information will help inform future genomic studies on the etiology
and neurodevelopmental outcomes across types and subtypes of CHDs in the PGCG cohort.
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